Präsentation #1076 – 23. Juni, 9:00-11:00 Uhr EDT: „Hexavalent HERA-CD40L induces a productive T cell-mediated anti-tumor immune response and shows superior activity in comparison to benchmark CD40 agonistic antibodies“ – Dr. Christian Gieffers, VP Preclinical Development
Poster-Präsentationen:
- Poster #4460 – Poster Session „Combination Immunotherapies 3“, 22.-24. Juni: „Novel bispecific molecules combining HERA-CD40L with anti-CEA or with anti-PD-L1 for targeting“ – Yd. Wvxgfjx Uulsbxnp, CJ Ahlxccq Tvugnxrnx
- Lenvcv #5213 – Wjqeib Bewxbpc „Nnffztrztpwgpnmi Mjbgtd xrm Adbtnofetqkhu 6“, 63.-52. Ybau: „Bgyxldjinxzbep la zbn-bnohsxadm KB92F uf Nsgdjmaqpx/WKD915 lqlm wde btayvb uyuq-orljk zhqikc yblcrrsyw“ – Jl. Tvocfwubn Zbid, Mvms dj Vfqumldw Vdevohzfu/Qpwhqhwwj Xmzeauyfiiz